Related Experiment Video
Updated: Nov 20, 2025
07:26
Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
Published on: July 14, 2021
5.3K
Reverse Cardiac Remodeling and ARNI Therapy.
Andrew Abboud1,2, James L Januzzi3,4,5
1Massachusetts General Hospital, 55 Fruit Street Yawkey 5B, Boston, MA, 02114, USA.
Current Heart Failure Reports
|January 22, 2021
Summary
Angiotensin receptor/neprilysin inhibitor (ARNI) therapy significantly reverses cardiac remodeling in heart failure with reduced ejection fraction. Recent trials confirm these benefits, prompting further research into broader applications.
Area of Science:
- Cardiology
- Pharmacology
- Heart Failure Research
Background:
- Cardiac remodeling is a key factor in heart failure progression.
- Guideline-directed medical and device therapy (GDMT) aims to manage heart failure.
- Angiotensin receptor/neprilysin inhibitor (ARNI) therapy is a novel treatment approach.
Purpose of the Study:
- To review reverse cardiac remodeling.
- To evaluate guideline-directed medical and device therapy (GDMT) in the context of ARNI therapy.
- To synthesize recent data on ARNI therapy's impact on cardiac remodeling.
Main Methods:
- Review of preliminary data on ARNI therapy.
- Analysis of prospective trials: PROVE-HF and EVALUATE-HF.
- Examination of biomarker and echocardiographic parameters.
Main Results:
- ARNI therapy demonstrated significant reversal of cardiac remodeling in heart failure with reduced ejection fraction (HFrEF).
- PROVE-HF and EVALUATE-HF confirmed marked improvements in remodeling parameters with ARNI use.
- Clinical benefits of sacubitril/valsartan in HFrEF are strongly linked to reverse cardiac remodeling.
Conclusions:
- ARNI therapy is effective in promoting reverse cardiac remodeling in HFrEF.
- Ongoing trials are investigating ARNI therapy in heart failure with preserved ejection fraction (HFpEF) and post-myocardial infarction.
- Future research should identify predictors of response to ARNI therapy.
Related Concept Videos
01:25Aortic Regurgitation III: Medical Management
174
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
174
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
671
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
671
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
199
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
199
01:29Cardiomyopathy V: Interprofessional Care
124
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
124
01:30Cardiomyopathy II: Dilated Cardiomyopathy
152
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
152
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
149
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
149